What is Noxopharm?
Noxopharm Limited operates at the intersection of advanced oncology research and immunology. The company distinguishes itself through two core technology platforms, Chroma and Sofra, which are engineered to address complex medical challenges including cancer and autoimmune conditions. Its lead clinical candidate, Veyonda, represents a strategic effort to enhance the efficacy of existing immunotherapies. By focusing on high-impact therapeutic areas, Noxopharm maintains a specialized market position as a developer of novel proprietary drugs designed to improve patient outcomes in challenging clinical environments.
How much funding has Noxopharm raised?
Noxopharm has raised a total of $23.1M across 2 funding rounds:
Debt
$15M
Share Placement
$8.1M
Debt (2019): $15M, investors not publicly disclosed
Share Placement (2020): $8.1M, investors not publicly disclosed
Key Investors in Noxopharm
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Noxopharm?
With the infusion of capital from its recent financing rounds, Noxopharm is set to prioritize the clinical progression of its pipeline. The strategic roadmap involves scaling the development of Veyonda and refining the application of its mRNA vaccine enhancement technologies. As the company transitions through this major enterprise-level funding phase, the focus will remain on achieving critical clinical trial milestones and expanding its intellectual property portfolio. Investors and stakeholders are monitoring the firm's ability to translate its research-heavy approach into tangible therapeutic solutions, which will be essential for long-term value creation in the competitive global biotech sector.
See full Noxopharm company page
